Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jefferies Reiterates Buy on Bristol-Myers Squibb (BMY) Following a 2017 Outlook
January 5, 2017 8:38 AM ESTJefferies reiterated a Buy rating and $69.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following a 2017 outlook.
Analyst Jeffrey Holford commented, "We expect 2017 to be a year of strong recovery for BMY as the CM-568 and CM-227 studies deliver data that... More
